×
About 2,890 results

ALLMedicine™ Autoimmune Hepatitis Center

Research & Reviews  1,070 results

Lymphocyte profile and immune checkpoint expression in drug-induced liver injury: an im...
https://doi.org/10.1002/cpt.2423
Clinical Pharmacology and Therapeutics; Cueto-Sanchez A, Niu H et. al.

Sep 21st, 2021 - The identification of specific human leukocyte antigen (HLA) risk alleles in drug-induced liver injury (DILI) points towards an important role of the adaptive immune system in DILI development. In this study we aimed to corroborate the role of an ...

Primary biliary cholangitis has the highest waitlist mortality in patients with cirrhos...
https://doi.org/10.1111/ctr.14479
Clinical Transplantation; Singal AK, Wong RJ et. al.

Sep 13th, 2021 - Data are sparse on etiology specific outcomes on waitlist (WL) and post-transplant outcomes among patients with acute on chronic liver failure (ACLF). In a retrospective cohort of 14,774 adults from UNOS database listed for LT with cirrhosis and A...

Review article: targeting the B cell activation system in autoimmune hepatitis.
https://doi.org/10.1111/apt.16574
Alimentary Pharmacology & Therapeutics; Czaja AJ

Sep 11th, 2021 - The B cell activation system, consisting of B cell activating factor and a proliferation-inducing ligand, may have pathogenic effects in autoimmune hepatitis. To describe the biological actions of the B cell activation system, indicate its possibl...

Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice.
https://doi.org/10.1007/s12016-021-08888-9 10.1038/nrdp.2018.17 10.1016/j.jaut.2012.11.002 10.1111/jgh.14746 10.1016/j.jhep.2015.06.030 10.1002/hep.31065 10.1016/S0016-5085(19)33223-8 10.1016/S0140-6736(73)92125-9 10.1093/oxfordjournals.qjmed.a067264 10.1016/j.jpeds.2019.11.028 10.1016/j.jaut.2018.10.004 10.1016/j.jhep.2004.08.002 10.1016/S0168-8278(20)31423-9 10.1016/j.jhep.2020.07.032 10.1016/S0140-6736(56)91483-0 10.1002/art.1780400909 10.1177/000992280404300709 10.1136/ard.2009.127100 10.1515/cclm-2018-0188 10.1111/j.1572-0241.2006.00479.x 10.1016/j.jaut.2013.08.001 10.1002/jcla.21813 10.1016/j.ejim.2020.02.001 10.3389/fimmu.2018.00609 10.1055/s-0029-1233533 10.3748/wjg.14.3374 10.1016/j.jaut.2018.07.006 10.1007/s004410050718 10.1196/annals.1398.047 10.1016/S0168-8278(99)80297-9 10.1002/hep.22322 10.1007/s13317-016-0075-0 10.1016/S0140-6736(65)92505-5 10.1136/jcp.29.5.403 10.1016/j.ejim.2017.10.006 10.1080/0891693021000054066 10.1002/hep.510260305 10.1002/hep.510240515 10.1136/jcp.2006.039404 10.1136/jcp.2005.027367 10.1097/MPG.0000000000001801 10.1016/j.jaut.2018.10.008 10.1053/jhep.2001.22131 10.1136/bmj.2.5910.80 10.1002/hep.1840070626 10.1007/s12016-014-8427-x 10.1002/hep.510250308 10.1016/0016-5085(92)91518-9 10.1172/JCI113949 10.1073/pnas.85.21.8256 10.1084/jem.168.2.801 10.1136/jcp.55.12.906 10.4049/jimmunol.170.3.1481 10.1172/JCI115443 10.1016/0016-5085(93)90657-X 10.1053/jhep.2002.35339 10.1136/bmjgast-2018-000203 10.1136/gut.37.3.406 10.1111/j.1365-2249.1994.tb06585.x 10.1177/039463200401700112 10.1097/00005176-200406001-00419 10.1016/S0140-6736(97)06478-7 10.1002/hep.1840040223 10.1073/pnas.84.2.551 10.1016/S0016-5085(96)70020-3 10.1016/S0140-6736(94)91966-6 10.1056/NEJM199006283222601 10.1016/S0016-5085(98)70484-6 10.1002/hep.1840080632 10.1016/S0016-5085(99)70186-1 10.1053/jhep.2001.27179 10.1136/gut.36.5.749 10.1186/1740-2557-4-2 10.1016/S0140-6736(87)90443-0 10.1002/hep.1840180102 10.1016/S0140-6736(87)92024-1 10.1053/jhep.2002.32092 10.1016/S0140-6736(00)02166-8 10.1053/jhep.2001.22218 10.1073/pnas.89.20.9739 10.1046/j.1365-2249.2000.01280.x 10.1053/jhep.2002.30699 10.1053/j.gastro.2008.07.029 10.1111/liv.14280 10.1016/S0140-6736(85)91147-X 10.1056/NEJM198806233182504 10.1007/s12016-017-8616-5 10.1002/hep.510280207 10.3748/wjg.14.3781 10.1016/S0168-8278(00)80241-X 10.1046/j.1440-1746.2000.02078.x 10.1136/gut.2008.157818 10.1016/0016-5085(95)90215-5 10.1186/1740-2557-1-2 10.1111/liv.13238 10.1159/000515361 10.1002/hep.21828 10.1002/hep.26666 10.1056/NEJMcpc0807822 10.1038/nrrheum.2017.74
Clinical Reviews in Allergy & Immunology; Terziroli Beretta-Piccoli B, Mieli-Vergani G et. al.

Sep 8th, 2021 - Circulating autoantibodies are a key diagnostic tool in autoimmune hepatitis (AIH), being positive in 95% of the cases if tested according to dedicated guidelines issued by the International Autoimmune Hepatitis Group. They also allow the distinct...

Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of cort...
https://doi.org/10.1016/j.jhep.2021.08.024
Journal of Hepatology; Björnsson HK, Gudbjornsson B et. al.

Sep 7th, 2021 - Infliximab has been associated with drug-induced liver injury (DILI), particularly drug-induced autoimmune hepatitis (DIAIH). DIAIH is commonly treated with corticosteroids, but there is limited data on the efficacy of corticosteroids in inflixima...

see more →

Guidelines  4 results

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF AUTOIMMUNE HEPATITIS.
https://doi.org/10.1016/j.clinre.2021.101772
Clinics and Research in Hepatology and Gastroenterology; Lemoinne S, Heurgue A et. al.

Aug 1st, 2021 - Autoimmune hepatitis (AIH) is a liver disease characterised by necrotico-inflammatory lesions of hepatocytes, the presence of specific autoantibodies and response to corticosteroid treatment. AIH must be considered in any patient with acute or chr...

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice ...
https://doi.org/10.1002/hep.31065
Hepatology (Baltimore, Md.); Mack CL, Adams D et. al.

Dec 22nd, 2019 - Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases.|2019|Mack CL,Adams D,Assis DN,Kerkar N,Manns MP,|diagnosis,drug therapy,

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

Diagnosis and management of autoimmune hepatitis.
https://doi.org/10.1002/hep.23584
Hepatology (Baltimore, Md.); Manns MP, Czaja AJ et. al.

Jun 1st, 2010 - Diagnosis and management of autoimmune hepatitis.|2010|Manns MP,Czaja AJ,Gorham JD,Krawitt EL,Mieli-Vergani G,|blood,diagnosis,drug therapy,immunology,pathology,

see more →

Drugs  7 results see all →

News  74 results

Worse Survival With Recurrent Autoimmune Hepatitis After Transplant
https://www.medscape.com/viewarticle/954067

Jul 1st, 2021 - Autoimmune hepatitis that recurs following a liver transplant can impair both graft survival and overall survival, results of a large international study showed. Among 736 patients with autoimmune hepatitis who underwent liver transplant and were ...

Incidence of Autoimmune Hepatitis May Be Rising
https://www.medscape.com/viewarticle/945131

Feb 2nd, 2021 - The incidence of autoimmune hepatitis (AIH) may be rising, according to a prospective population-based study conducted in New Zealand. From 2008 to 2016, the rising incidence of AIH led to a 40% increase in point prevalence, reported lead author M...

Treating Liver Disease During COVID-19: New Recommendations
https://www.medscape.com/viewarticle/930411

May 14th, 2020 - Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The COVID-19 pandemic presents myriad challenges to hepatologists, gastroenterologists, transplant programs, primary care providers, and, of course, their patien...

AASLD: Liver transplants should proceed despite COVID-19
https://www.mdedge.com/gihepnews/article/220026/coronavirus-updates/aasld-liver-transplants-should-proceed-despite-covid-19?channel=63993
M. Alexander Otto, MDedge News

Apr 1st, 2020 - In liver transplant recipients or patients with autoimmune hepatitis on immunosuppressive therapy, acute cellular rejection or disease flare should not be presumed in the face of active coronavirus disease 2019 (COVID-19), according to the America.

CymaBay Therapeutics scraps two studies of liver drug; shares plunge
https://www.reuters.com/article/us-cymabay-nash/cymabay-therapeutics-scraps-two-studies-of-liver-drug-shares-plunge-idUSKBN1XZ1MC

Nov 25th, 2019 - (Reuters) - CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage trials of its liver disease drug, after biopsies found a type of liver damage in some patients, sending its shares down over 75%. The drug developer said it had obs...

see more →

Patient Education  1 results see all →